ABSTRACT
BACKGROUND The mental health of children and adolescents is a growing public health concern, with increasing rates of depression and anxiety impacting their emotional, social, and academic well-being. In Japan, access to timely psychiatric care is limited, leading to extended waiting periods that can range from three months to a year. AI-driven chatbots, such as emol, which integrate Acceptance and Commitment Therapy (ACT), show potential as digital solutions to support young patients during these waiting times. The AI chatbot emol was selected based on a comprehensive review of Japanese mental health technology applications, including in-person evaluations with company representatives.
METHODS This exploratory, parallel-group randomized controlled trial examined the feasibility of using AI chatbot emol with pediatric and adolescent individuals on psychiatric waiting lists. Participants aged 12-18 years were recruited from four hospitals in Kanagawa Prefecture and randomly assigned to either an intervention group, receiving eight weekly chatbot sessions, or a control group, receiving standard mental health information. The primary outcome was change in Patient Health Questionnaire-9 (PHQ-9) scores from pre- to post-intervention. Secondary assessments, such as voice and writing pressure analysis, provided additional engagement metrics, with data collected at baseline, during the intervention, and at week 9.
FINDINGS Of the 96 eligible individuals on psychiatric waiting lists, eight expressed interest, and three provided initial consent. However, all participants subsequently withdrew or were excluded, resulting in no evaluable data for analysis. Low engagement may have been influenced by the perceived irrelevance of digital tools, complex protocols, and privacy concerns.
CONCLUSION Significant barriers to engagement suggest that digital interventions may need simpler protocols and trusted environments to improve feasibility. Future studies could test these interventions in supportive settings, like schools or community centers, to enhance accessibility and participation among youth.
FUNDING This study was supported by the Japan Science and Technology Agency (JST) Grant Number JPMJPF1234. The funder had no role in study design, data collection, analysis, interpretation, or manuscript submission decisions.
Competing Interest Statement
This study was supported by the Japan Science and Technology Agency (JST) Grant Number JPMJPF1234. The funder had no role in study design, data collection, analysis, interpretation, or manuscript submission decisions. SS, NS, MO, MI, MT, HY, MT, TM have no conflict of interest. Individually, JF received research grants from KAKENHI (21K01994). JF also served as a member of an advisory board for Seisa Yokohama Educational Counseling Center. YY received consulting fees from ZEBRA HOLDINGS Inc. In this study, Emol Inc. provided the AI Chatbot emol at a discounted rate, ZEBRA HOLDINGS Inc. contributed research funding, and SHIN4NY Inc. offered devices at a reduced cost. This study was funded by the Japan Science and Technology Agency (JST) under the Co-creation Opportunity Formation Support Program (COI-NEXT), FY2022 to 2031. The supporting companies and the funding agency had no role in study design, data collection, analysis, interpretation, or manuscript submission decisions.
Clinical Trial
jRCT1032230427
Clinical Protocols
Funding Statement
This study was supported by the Japan Science and Technology Agency (JST) Grant Number JPMJPF1234.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Approval for the study was granted by the Ethics Committee of Yokohama City University (Approval number F230907001).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
